Evidence map›Paper›PMID 25896705›Full record

ArticleAntimicrobial agents and chemotherapy2015

Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.

Brunella Posteraro, Teresa Spanu, Barbara Fiori, Flavio De Maio, Elena De Carolis, Alessia Giaquinto, Valentina Prete, Giulia De Angelis, Riccardo Torelli, Tiziana D'Inzeo and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Rapid antifungal susceptibility testing from positive blood cultures using direct gradient diffusion: a prospective study.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Observational
  4. BeyondJournal of fungi (Basel, Switzerland) · 2026
    Article
  5. Article
  6. Candidemia due toMedical mycology case reports · 2025
    Article
  7. Article
  8. Molecular Identification ofAdvanced biomedical research · 2025
    Article
  9. Article
  10. Observational
  11. Article
  12. Meyerozyma guilliermondii species complex: review of current epidemiology, antifungal resistance, and mechanisms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Brunella PosteraroInstitute of Public Health (Section of Hygiene), Università Cattolica del Sacro Cuore, Rome, Italy.
Teresa SpanuInstitute of Microbiology, Università Cattolica del Sacro Cuore, Rome, Italy.
Barbara FioriInstitute of Microbiology, Università Cattolica del Sacro Cuore, Rome, Italy.
Flavio De MaioInstitute of Microbiology, Università Cattolica del Sacro Cuore, Rome, Italy.
Elena De CarolisInstitute of Microbiology, Università Cattolica del Sacro Cuore, Rome, Italy.
Alessia GiaquintoInstitute of Microbiology, Università Cattolica del Sacro Cuore, Rome, Italy.
Valentina PreteInstitute of Microbiology, Università Cattolica del Sacro Cuore, Rome, Italy.
Giulia De AngelisInstitute of Microbiology, Università Cattolica del Sacro Cuore, Rome, Italy.
Riccardo TorelliInstitute of Microbiology, Università Cattolica del Sacro Cuore, Rome, Italy.
Tiziana D'InzeoInstitute of Microbiology, Università Cattolica del Sacro Cuore, Rome, Italy.
Antonietta VellaInstitute of Microbiology, Università Cattolica del Sacro Cuore, Rome, Italy.
Alessio De LucaHospital Pharmacy, Università Cattolica del Sacro Cuore, Rome, Italy.
Mario TumbarelloInstitute of Infectious Diseases, Università Cattolica del Sacro Cuore, Rome, Italy.
Walter RicciardiInstitute of Public Health (Section of Hygiene), Università Cattolica del Sacro Cuore, Rome, Italy.
Maurizio SanguinettiInstitute of Microbiology, Università Cattolica del Sacro Cuore, Rome, Italy msanguinetti@rm.unicatt.it.
Università Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sensititre YeastOne (SYO) is an affordable alternative to the Clinical and Laboratory Standards Institute (CLSI) reference method for antifungal susceptibility testing. In this study, the MICs of yeast isolates from 1,214 bloodstream infection episodes, generated by SYO during hospital laboratory activity (January 2005 to December 2013), were reanalyzed using current CLSI clinical breakpoints/epidemiological cutoff values to assign susceptibility (or the wild-type [WT] phenotype) to systemic antifungal agents. Excluding Candida albicans (57.4% of all isolates [n = 1,250]), the most predominant species were Candida parapsilosis complex (20.9%), Candida tropicalis (8.2%), Candida glabrata (6.4%), Candida guilliermondii (1.6%), and Candida krusei (1.3%). Among the non-Candida species (1.9%), 7 were Cryptococcus neoformans and 17 were other species, mainly Rhodotorula species. Over 97% of Candida isolates were susceptible (WT phenotype) to amphotericin B and flucytosine. Rates of susceptibility (WT phenotype) to fluconazole, itraconazole, and voriconazole were 98.7% in C. albicans, 92.3% in the C. parapsilosis complex, 96.1% in C. tropicalis, 92.5% in C. glabrata, 100% in C. guilliermondii, and 100% (excluding fluconazole) in C. krusei. The fluconazole-resistant isolates consisted of 6 C. parapsilosis complex isolates, 3 C. glabrata isolates, 2 C. albicans isolates, 2 C. tropicalis isolates, and 1 Candida lusitaniae isolate. Of the non-Candida isolates, 2 C. neoformans isolates had the non-WT phenotype for susceptibility to fluconazole, whereas Rhodotorula isolates had elevated azole MICs. Overall, 99.7% to 99.8% of Candida isolates were susceptible (WT phenotype) to echinocandins, but 3 isolates were nonsusceptible (either intermediate or resistant) to caspofungin (C. albicans, C. guilliermondii, and C. krusei), anidulafungin (C. albicans and C. guilliermondii), and micafungin (C. albicans). However, when the intrinsically resistant non-Candida isolates were included, the rate of echinocandin nonsusceptibility reached 1.8%. In summary, the SYO method proved to be able to detect yeast species showing antifungal resistance or reduced susceptibility.

Indexed as

AgedAged, 80 and overAntifungal AgentsCross InfectionDrug Resistance, FungalFemaleHospitals, TeachingHumansItalyMaleMicrobial Sensitivity TestsMiddle AgedMycosesYeastsAntifungal Agents

Identifiers

PMID25896705
PMCPMC4468684
OpenAlexW1508443003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.